Biomarck is pleased to announce its inclusion on COVID-19 Drug Treatment Trackers: Milken Institute COVID-19 Treatment and Vaccine Tracker | Artis Ventures

Andrew Davis


Mr. Davis is currently an advisor at Biomarck. He has significant experience across the Business Development and Merger’s and Acquisitions landscape, having led over 70 transactions in his career.

Mr. Davis has served as the Chief BD/M&A Officer at iNova Pharmaceuticals since September of 2017, leading all company transactions along with serving as a member of the company’s executive team. Additionally, Mr. Davis currently serves on the board of directors for Utility Therapeutics. Prior to iNova Mr. Davis served as the Head of Oncology Business Development at Merck since December 2016. Prior to Merck, Mr. Davis served as the SVP of Business Development of Valeant Pharmaceuticals (now Bausch Health Companies) a global pharmaceutical, consumer products and medical device company, leading all transactions for the company from 2014 to December 2016. Prior this this role Mr. Davis had increasing roles of responsibility within the Business Development function at Valeant, joining the company in 2012. Prior to Valeant, he served as a management consultant at McKinsey & Co. focused on the healthcare space from 2007-2012. Mr. Davis received his B.A. in Economics from Boston University in Boston Massachusetts.